Ignite Creation Date:
2024-10-25 @ 7:59 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06548672
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-11
Brief Title:
A Study to Assess the Safety Pharmacokinetics and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase IaIb Open-Label Dose Escalation and Dose Expansion Study to Evaluate the Safety Tolerability Pharmacokinetics PK and Preliminary Efficacy of BC3195 in Patients With Locally Advanced or Metastatic Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a phase IaIb open-label dose escalation and dose expansion study to evaluate the safety tolerability pharmacokinetics and antitumor activity of BC3195 in subjects with locally advanced or metastatic solid tumors in whom standard treatment has failed either due to disease progression or intolerance This study will consist of two parts Dose escalation Part 1 and dose expansion Part 2 Each part will include a screening period a treatment period and follow-up period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None